Search research articles
Contact Us
Filters
Showing results (11-20 of 35) with videos related to
Page
of 4
Sort By:
Open Forum Infectious Diseases
|
September 26, 2022
Manufacturing Process of SER-109, a Purified Investigational Microbiome Therapeutic, Reduces Risk of Coronavirus Transmission From Donor Stool
Christopher McChalicher, Ahmad Abdulaziz, S Steve Zhou, et al.
Gut Microbes
|
September 18, 2024
End-to-end donor screening and manufacturing controls: complementary quality-based strategies to minimize patient risk for donor-derived microbiome therapeutics
Jason Goldsmith, Sarah Tomkovich, John G Auniņš, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
May 18, 2006
Acute hepatitis C virus infection in incarcerated injection drug users
Barbara H McGovern, Alysse Wurcel, Arthur Y Kim, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 31, 2007
Managing symptomatic drug-induced liver injury in HIV-hepatitis C virus-coinfected patients: a role for interferon
Barbara H McGovern, Christopher Birch, M Tauheed Zaman, et al.
Topics in Antiviral Medicine
|
April 19, 2013
Impact of new therapeutics for hepatitis C virus infection in incarcerated populations
Anne S Spaulding, Arthur Y Kim, Amy Jo Harzke, et al.
The Journal of Infectious Diseases
|
August 4, 2023
Manufacturing Processes of a Purified Microbiome Therapeutic Reduce Risk of Transmission of Potential Bacterial Pathogens in Donor Stool
Christopher W J McChalicher, Mary-Jane Lombardo, Sahil Khanna, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 12, 2023
Impact of a Purified Microbiome Therapeutic on Abundance of Antimicrobial Resistance Genes in Patients With Recurrent Clostridioides difficile Infection
Timothy J Straub, Mary-Jane Lombardo, Jessica A Bryant, et al.
Annals of Internal Medicine
|
June 30, 2015
Underascertainment of acute hepatitis C virus infections in the U.S. surveillance system: a case series and chart review
Shauna Onofrey, Jasneet Aneja, Gillian A Haney, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
June 29, 2006
Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients
Barbara H McGovern, Jeremy S Ditelberg, Lynn E Taylor, et al.
International Journal of Epidemiology
|
December 4, 2012
Cohort profile: the international collaboration of incident HIV and hepatitis C in injecting cohorts (InC3) study
Jason Grebely, Meghan D Morris, Thomas M Rice, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 35) with videos related to
Sort By:
Page
of 4
Open Forum Infectious Diseases
|
September 26, 2022
Manufacturing Process of SER-109, a Purified Investigational Microbiome Therapeutic, Reduces Risk of Coronavirus Transmission From Donor Stool
Christopher McChalicher, Ahmad Abdulaziz, S Steve Zhou, et al.
Gut Microbes
|
September 18, 2024
End-to-end donor screening and manufacturing controls: complementary quality-based strategies to minimize patient risk for donor-derived microbiome therapeutics
Jason Goldsmith, Sarah Tomkovich, John G Auniņš, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
May 18, 2006
Acute hepatitis C virus infection in incarcerated injection drug users
Barbara H McGovern, Alysse Wurcel, Arthur Y Kim, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 31, 2007
Managing symptomatic drug-induced liver injury in HIV-hepatitis C virus-coinfected patients: a role for interferon
Barbara H McGovern, Christopher Birch, M Tauheed Zaman, et al.
Topics in Antiviral Medicine
|
April 19, 2013
Impact of new therapeutics for hepatitis C virus infection in incarcerated populations
Anne S Spaulding, Arthur Y Kim, Amy Jo Harzke, et al.
The Journal of Infectious Diseases
|
August 4, 2023
Manufacturing Processes of a Purified Microbiome Therapeutic Reduce Risk of Transmission of Potential Bacterial Pathogens in Donor Stool
Christopher W J McChalicher, Mary-Jane Lombardo, Sahil Khanna, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 12, 2023
Impact of a Purified Microbiome Therapeutic on Abundance of Antimicrobial Resistance Genes in Patients With Recurrent Clostridioides difficile Infection
Timothy J Straub, Mary-Jane Lombardo, Jessica A Bryant, et al.
Annals of Internal Medicine
|
June 30, 2015
Underascertainment of acute hepatitis C virus infections in the U.S. surveillance system: a case series and chart review
Shauna Onofrey, Jasneet Aneja, Gillian A Haney, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
June 29, 2006
Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients
Barbara H McGovern, Jeremy S Ditelberg, Lynn E Taylor, et al.
International Journal of Epidemiology
|
December 4, 2012
Cohort profile: the international collaboration of incident HIV and hepatitis C in injecting cohorts (InC3) study
Jason Grebely, Meghan D Morris, Thomas M Rice, et al.
Page
of 4